soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo SOUL trial shows oral semaglutide

95% CI: 0.044, 0.362) and females (, 0.136

For people interested in an alternative drug to Ozempic, some alternatives include Wegovy, Rybelsus, Mounjaro, Trulicity, and metformin

Listing Images That Convert For the Amazon listing, we designed high-impact visuals highlighting GLP-1 Strengths key benefits: Boosts GLP-1 naturally Supports metabolism Reduces body fat Enhances strength and endurance Maintains muscle and balances glucose Each image pairs strong headlines with simple iconography and bold yellow callouts to make benefits instantly scannable

Hydration : Adequate fluid intake is crucial, particularly when using laxatives or increasing dietary fibre